Traditional approaches to growth in biopharma are no longer sustainable
pharmaphorum
AUGUST 5, 2022
Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And, for M&A deals valued at more than $500M, the average takeout premium in biopharma has grown from 51% in 2018, to roughly 71% in 2021. About the Author.
Let's personalize your content